This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henry, K. W.
Right arrow Articles by Edlind, T. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henry, K. W.
Right arrow Articles by Edlind, T. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1999, p. 1968-1974, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Antagonism of Azole Activity against Candida albicans following Induction of Multidrug Resistance Genes by Selected Antimicrobial Agents

Karl W. Henry,* M. Cristina Cruz,dagger Santosh K. Katiyar, and Thomas D. Edlind

Department of Microbiology and Immunology, MCP Hahnemann School of Medicine, Philadelphia, Pennsylvania 19129

Received 6 November 1998/Returned for modification 27 January 1999/Accepted 28 May 1999

Antifungal azoles (e.g., fluconazole) are widely used for prophylaxis or treatment of Candida albicans infections in immunocompromised individuals, such as those with AIDS. These individuals are frequently treated with a variety of additional antimicrobial agents. Potential interactions between three azoles and 16 unrelated drugs (antiviral, antibacterial, antifungal, and antiprotozoal agents) were examined in vitro. Two compounds, tested at concentrations achievable in serum, demonstrated an antagonistic effect on azole activity against C. albicans. At fluconazole concentrations two to four times the 50% inhibitory concentration, C. albicans growth (relative to treatment with fluconazole alone) increased 3- to 18-fold in the presence of albendazole (2 µg/ml) or sulfadiazine (50 µg/ml). Antagonism (3- to 78-fold) of ketoconazole and itraconazole activity by these compounds was also observed. Since azole resistance has been correlated with overexpression of genes encoding efflux proteins, we hypothesized that antagonism results from drug-induced overexpression of these same genes. Indeed, brief incubation of C. albicans with albendazole or sulfadiazine resulted in a 3-to->10-fold increase in RNAs encoding multidrug transporter Cdr1p or Cdr2p. Zidovudine, trimethoprim, and isoniazid, which were not antagonistic with azoles, did not induce these RNAs. Fluphenazine, a known substrate for Cdr1p and Cdr2p, strongly induced their RNAs and, consistent with our hypothesis, strongly antagonized azole activity. Finally, antagonism was shown to require a functional Cdr1p. The possibility that azole activity against C. albicans is antagonized in vivo as well as in vitro in the presence of albendazole and sulfadiazine warrants investigation. Drug-induced overexpression of efflux proteins represents a new and potentially general mechanism for drug antagonism.

* Corresponding author. Mailing address: Department of Microbiology and Immunology, MCP Hahnemann School of Medicine, 2900 Queen Ln., Philadelphia, PA 19129. Phone: (215) 991-8374. Fax: (215) 848-2271. E-mail: henryk1{at}auhs.edu.

dagger Present address: Department of Genetics, Duke University Medical Center, Durham, NC 27710.

Antimicrobial Agents and Chemotherapy, August 1999, p. 1968-1974, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Vogel, M., Hartmann, T., Koberle, M., Treiber, M., Autenrieth, I. B., Schumacher, U. K. (2008). Rifampicin induces MDR1 expression in Candida albicans. J Antimicrob Chemother 61: 541-547 [Abstract] [Full Text]  
  • Banerjee, D., Lelandais, G., Shukla, S., Mukhopadhyay, G., Jacq, C., Devaux, F., Prasad, R. (2008). Responses of Pathogenic and Nonpathogenic Yeast Species to Steroids Reveal the Functioning and Evolution of Multidrug Resistance Transcriptional Networks. Eukaryot Cell 7: 68-77 [Abstract] [Full Text]  
  • Fardeau, V., Lelandais, G., Oldfield, A., Salin, H., Lemoine, S., Garcia, M., Tanty, V., Le Crom, S., Jacq, C., Devaux, F. (2007). The Central Role of PDR1 in the Foundation of Yeast Drug Resistance. J. Biol. Chem. 282: 5063-5074 [Abstract] [Full Text]  
  • Quan, H., Cao, Y.-Y., Xu, Z., Zhao, J.-X., Gao, P.-H., Qin, X.-F., Jiang, Y.-Y. (2006). Potent In Vitro Synergism of Fluconazole and Berberine Chloride against Clinical Isolates of Candida albicans Resistant to Fluconazole. Antimicrob. Agents Chemother. 50: 1096-1099 [Abstract] [Full Text]  
  • Edlind, M. P., Smith, W. L., Edlind, T. D. (2005). Effects of Cetylpyridinium Chloride Resistance and Treatment on Fluconazole Activity versus Candida albicans. Antimicrob. Agents Chemother. 49: 843-845 [Abstract] [Full Text]  
  • Te Dorsthorst, D. T. A., Verweij, P. E., Meis, J. F. G. M., Punt, N. C., Mouton, J. W. (2004). In Vitro Interactions between Amphotericin B, Itraconazole, and Flucytosine against 21 Clinical Aspergillus Isolates Determined by Two Drug Interaction Models. Antimicrob. Agents Chemother. 48: 2007-2013 [Abstract] [Full Text]  
  • Frade, J. P., Warnock, D. W., Arthington-Skaggs, B. A. (2004). Rapid Quantification of Drug Resistance Gene Expression in Candida albicans by Reverse Transcriptase LightCycler PCR and Fluorescent Probe Hybridization. J. Clin. Microbiol. 42: 2085-2093 [Abstract] [Full Text]  
  • Afeltra, J., Vitale, R. G., Mouton, J. W., Verweij, P. E. (2004). Potent Synergistic In Vitro Interaction between Nonantimicrobial Membrane-Active Compounds and Itraconazole against Clinical Isolates of Aspergillus fumigatus Resistant to Itraconazole. Antimicrob. Agents Chemother. 48: 1335-1343 [Abstract] [Full Text]  
  • Gauthier, C., Weber, S., Alarco, A.-M., Alqawi, O., Daoud, R., Georges, E., Raymond, M. (2003). Functional Similarities and Differences between Candida albicans Cdr1p and Cdr2p Transporters. Antimicrob. Agents Chemother. 47: 1543-1554 [Abstract] [Full Text]  
  • Henry, K. W., Nickels, J. T., Edlind, T. D. (2002). ROX1 and ERG Regulation in Saccharomyces cerevisiae: Implications for Antifungal Susceptibility. Eukaryot Cell 1: 1041-1044 [Abstract] [Full Text]  
  • Smith, W. L., Edlind, T. D. (2002). Histone Deacetylase Inhibitors Enhance Candida albicans Sensitivity to Azoles and Related Antifungals: Correlation with Reduction in CDR and ERG Upregulation. Antimicrob. Agents Chemother. 46: 3532-3539 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»